Carcinoma in situ of the breast: Correlation of histopathology to immunohistochemical markers and DNA ploidy

Breast Cancer Research and Treatment

Volumn 60, Issue 3, 2000, Pages 219-226

  Ottesen, Gyda Lolk ^a   Christensen, Ib Jarle ^b   Larsen, Jørgen K ^b   Larsen, Jacob ^b   Baldetorp, Bo ^b   Linden, Thomas ^c   Hansen, Bodil ^d   Andersen, Johan ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Breast carcinoma in situ; DNA ploidy; Histopathology; Immunohistochemistry; Invasive carcinoma

Indexed keywords

DNA; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY KI 67; PROGESTERONE RECEPTOR; PROTEIN P53; STEROID RECEPTOR; TUMOR MARKER;

ANEUPLOIDY; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CARCINOMA IN SITU; CELL HETEROGENEITY; CELL NUCLEUS; CELL PROLIFERATION; COMEDO; CONTROLLED STUDY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PLOIDY; PRIORITY JOURNAL; TISSUE NECROSIS; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA, NEOPLASM; FEMALE; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MASTECTOMY; NECROSIS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PLOIDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0033935483     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006453420088     Document Type: Article

References (30)

1. 1. Zhuang Z, Merino MJ, Chuaqui R, Liotta LA, Emmert-Buck MR: Identical allelic loss on chromosome 11Q13 in microdissected in situ and invasive human breast cancer. Cancer Res 55: 467-471, 1995
2. 2. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire-WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23: 974-979, 1992
3. 3. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R: Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 69: 1174-1181, 1992
4. 4. Iglehart JD, Kerns BJ, Huper G, Marks JR: Maintenance of DNA content and erbB-2 alterations in intraductul and invasive phases of mammary cancer. Breast Cancer Res Treat 34: 253-263, 1995
5. 5. Maguire HC, Hellman ME, Greene MI, Yeh I: Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast. Pathobiology 60: 117-121, 1992
6. 6. Ottesen GL, Christensen IJ, Larsen JK, Hansen B, Andersen JA: Flow cytometric DNA analysis of breast cancers with predominance of carcinoma in situ: A comparison of the premalignant and malignant components. Clin Cancer Res 1: 881-888, 1995
7. 7. Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM: C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer 68: 331-334, 1991
8. 8. Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Andersen JA: Carcinoma in situ of the female breast. Ten years follow-up results of a prospective nationwide study, (submitted)
9. 9. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA: Ductal carcinoma in situ of Ihe female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol 16: 1183-1196, 1992
10. 10. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA: Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol 17: 14-21, 1993
11. 11. WHO: Histological Typing of Breast Tumours. 2nd ed., Geneva, 1981
12. 12. Azzopardi JG: Problems in Breast Pathology. WB Saunders, London, 1979, pp 113-166, 192-233
13. 13. Ottesen GL, Christensen IJ, Larsen JK, Christiansen J, Hansen B, Andersen JA. DNA analysis of in situ ductal carcinoma of the breast via flow cytometry. Cytometry: Comm Clin Cytometry 22: 168-176, 1995
14. 14. Ottesen GL, Christensen IJ, Larsen JK, Larsen J, Christiansen J, Baldetorp B, Linden T, Hansen B, Andersen JA: DNA ploidy analysis in breast cancer: a comparison of unfixed and fixed tissue, by image and flow cytometry. Anal Quant Cytol Histol 19: 413-422, 1997
15. 15. Wang N, Pan Y, Heiden T, Tribukait B: Improved method for release of cell nuclei from paraffin-embedded cell malerial of squamous cell carcinomas. Cytometry 14: 931-935, 1993
16. 16. Vindeløv LL, Christensen IJ: A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. Cytometry 11: 753-770, 1990
17. 17. Bobrow LG, Happerfield LC, Gregory WM, Millis RR: Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 176: 333-341, 1995
18. 18. Bartkova J, Barnes DM, Millis RR, Gullick WJ: Immunohistochemical demonstration of c-erhB-2 protein in mammary ductal carcinoma. Hum Pathol 21: 1164-1167, 1990
19. 19. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS: Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erhB-2 protein. Cancer 75: 2123-2131, 1995
20. 20. Mack L, Kerkvliet N, Doig G, O'Malley FP: Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. Hum Pathol 28: 974-979, 1997.
21. 21. Poller DN, Snead DR, Roberts EC, Galea M, Bell JA, Gilmour A, Elston CW, Blamey RW, Ellis IO: Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer 68: 156-161, 1993
22. 22. Poller DN, Roberts BC, Bell JA, Elston CW, Blarney RW, Ellis IO: p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 25: 463-468, 1993
23. 23. De Potter CR, Schelfhout AM, Verbeeck P, Lakhani SR, Brunken R, Schroeter CA, Van den Tweel JG, Schauer AJ, Sloane JP: Neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast. Hum Pathol. 26:601-606, 1995
24. 24. Schimmelpenning H, Eriksson ET, Pallis L, Skoog L, Cedermark B, Auer GU: Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary carcinoma in situ. Am J Clin Pathol 97: S48-S52, 1992
25. 25. Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme D, Validire P, Sastre-Garau X. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 11: 208-214, 1994
26. 26. Lagios MD: Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am 70: 853-871, 1990
27. 27. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, Lewinsky B, Gamagami P, Slamon DJ: Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345: 1154-1157, 1995
28. 28. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B: Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11: 167-180, 1994
29. 29. Consensus conference on the classification of ductal carcinoma in situ. Cancer 80: 1798-1802, 1997
30. 30. Smith HS, Lu Y, Deng G, Martinez O, Krams S, Ljung BM, Thor A, Lagios M: Molecular aspects of early stages of breast cancer progression. J Cell Biochem Suppl 17G: 144-152, 1993